Partner Kerry S. Taylor, Ph.D. was quoted in, “US Perspectives: In US, New Legal Ploy May Protect Bad Patents,” an article published in Intellectual Property Watch.
Excerpt: The drug maker’s stock price had fallen over 20 percent, as the company faced two legal challenges to the patents on its blockbuster drug, Restasis. Then, on 16 October, Allergan lost one of those challenges. A US court found the patents invalid. Allergan vowed to appeal, thus maintaining its monopoly on the drug until a final court determination, which could be over a year away.
Read Full Article Here >> (Subscription required)